Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PCORI Board Approves Definition Of “Patient-Centered Outcomes Research,” Despite Some Objections

This article was originally published in The Pink Sheet Daily

Executive Summary

Time already spent on developing and refining the definition outweighs certain members’ objections to the final version developed by the Patient-Centered Outcomes Research Institute’s Methodology Committee.

You may also be interested in...



Not A “Cookbook”: PCORI Board Prepares For Release Of Research Methodology Report

The Patient-Centered Outcomes Research Institute will develop a multifaceted plan to solicit meaningful feedback on its forthcoming methodology committee report, including setting appropriate expectations for the document, members of the PCORI board said during a May 21 meeting.

PCORI Seeks Public Input On Definition Of "Patient-Centered Outcomes Research"

Outreach efforts include web-based survey as the public/private Patient-Centered Outcomes Research Institute looks to finish a key part of its foundation and move forward on research activities.

FDA 2015 Budget Increase Proposal Leans On Food Safety User Fees

Food safety programs would get the largest increase in the White House’s proposed fiscal 2015 FDA budget, and increases in user fee programs are proposed as key drivers for the boost. The agency’s overall budget would grow $335 million to $4.7 billion in the proposal.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS073845

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel